Glucagon-like相关论文
A common challenge in managing kidney transplant recipients(KTR)is posttransplant diabetes mellitus(PTDM)or diabetes mel......
Psoriasis and diabetes shared common underlying pathophysiological mechanisms.Emerging data suggested that antidiabetic ......
BACKGROUND Nonalcoholic fatty liver disease(NAFLD)is a major chronic liver disorder worldwide,and there is no establishe......
,Effects of liraglutide and sibutramine on food intake,palatability, body weight and glucose toleran
...
目的探讨68Ga-艾塞那肽(exendin-4) PET/CT胰高血糖素样肽-1(GLP-1)受体显像在胰岛素瘤定位诊断中的价值，并与常规影像学诊断方法进......
目的观察早期胰岛素泵治疗对新诊断的2型糖尿病(T2DM)患者血胰升血糖素样肽1(GLP-1)的影响。方法选择T2DM患者100例,根据病程分为......
目的 观察肠易激综合征( IBS)不同亚型模型大鼠血清胰高糖素样肽(GLP)-1及结肠组织中GLP-1受体的变化,初步探讨GLP-1及其受体在IBS......
Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflam
Glucagon-like peptide1(GLP-1)is secreted from Langerhans cells in response to oral nutrient intake.Glucagon-like peptide......
非酒精性脂肪性肝病在全球发病率持续上升,由于其复杂的发病机制,尚未开发出有效的治疗药物。该病若未得到及时治疗,可能加剧糖尿......
Cytoprotection and Cytothetic Effects of GLP-2 on Enterocytes from a Weaned Piglet Injured by β-cong
The experiment was conducted to study the effects and possible mechanism of GLP-2 on proliferation,metabolism and apopto......
目的:探讨胰高血糖样肽1(GLP-1)类似物利拉鲁肽对非酒精性脂肪肝(NAFLD)大鼠补体因子H相关蛋白(CFHR)1~5表达的影响。方法:对照组......
Glucagon-like peptide-1 protects against cardiac microvascular endothelial cells injured by high glu
Objective:To investigate the protective effect of glucagon-like peptid-1(GLP-l) against cardiac microvascular endothelia......
The Short- and Long-Term Effect of Liraglutide on the Beta Cell Function in Type 2 Diabetic Patients
Glucagon-like peptide 1 (GLP-1) is a hormone, inducing glucose-dependent stimulation of insulin secretion from beta cell......
Effects of glucagon-like peptide 1 analogs in combination with insulin on myocardial infarct size in
AIM To evaluate the effects of glucagon-like peptide-1 analogs(GLP-1a)combined with insulin on myocardial ischemiareperf......
Type 2 diabetes (T2D) is a disorder characterized by chronic inflated blood glucose levels (hyperglycemia), at first due......
Development of therapeutic options on type 2 diabetes in years: Glucagon-like peptide-1 receptor ago
Diabetes mellitus (DM) is a chronic metabolic disease characterized by hyperglycemia.Type 2 diabetes (T2DM) accounting f......
Recently,glucagon-like peptide-1(GLP-1)receptor agonists have become a cornerstone for the treatment of obese patients w......
Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates kidney injury in murine mode
AIM To investigate the role of glucagon-like peptide-1(GLP-1)/glucagon receptors coagonist on renal dysfunction associat......
Prevention of macrovascular complications in patients with type 2 diabetes mellitus: Review of cardi
Lack of conclusive beneficial effects of strict glycemic control on macrovascular complications has been very frustratin......
Objective: To study the effect of glucagon-like peptide-1 (GLP-1) agonist on osteoblast proliferation and related signal......
Can Sitaglipten Attenuate Hypertension, Myocardial Changes and Vascular Reactivity Induced by Long T
Background: Glucagon-like peptide-1 (GLP-1) is an incretin hormone with insulinotropic properties that regulates glucose......
The Possible Role of the Incretin Enhancer Sitaglipten, in Renal Ischemic Reperfusion Injury in Type
Background: Diabetes mellitus (DM) especially type 2 is a major health problem and diabetic nephropathy is the main caus......
Elevated glucagon-like peptide-1 on a high-fat diet feeding prevents the incidence of diabetes melli
Nutritional regulation plays a critical role to reduce the incidence or progression of diabetes mellitus. In this study,......
目的：探讨维格列汀对戊四氮（PTZ）诱导的癫痫模型中胰高血糖素样肽1（GLP-1）及胰高血糖素样肽1受体（GLP-1R）的影响而发挥抗癫痫作用。方法脑......
Objective Doxorubicin(Dox)is an effective antitumor drug,which is limited due to its lethal cardiac injury in clinical a......
Exercise therapy is essential for the management of type 2 diabetes(T2D).However,patients with T2D show lower physical a......
Risk of pancreatic adverse events associated with the use of glucagon-like peptide-1 receptor agonis
...
Non-alcoholic fatty liver disease(NAFLD)is the predominant cause of chronic liver disease worldwide.NAFLD progresses in ......
Is there a role for glucagon-like peptide-1 receptor agonists in the management of diabetic nephropa
Chronic kidney disease constitutes a major microvascular complication of diabetes mellitus.Accumulating data suggest tha......
AIM:To evaluate the efficacy and safety of the addition of vildagliptin to low-dose metformin and compare it to an uptit......
Glucagon-like peptide-1(GLP-1)receptor agonists result in greater improvements in glycemic control than placebo and prom......
There are many advantages of combining incretin therapy[glucagon-like peptide-1(GLP-1)receptor agonists and dipeptidyl p......
Long-acting glucagon-like peptide-1 （GLP-1） analoguesmarketed for type 2 diabetes （T2D） treatment havebeen showing positive ......
Incretin-based therapies have revolutionized the medicalmanagement of type 2 diabetes mellitus （T2DM）in the 21st century. ......
Though the pathophysiology of clinical obesity is undoubtedly multifaceted, several lines of clinical evidence implicate......
Prediction of the effect on antihyperglycaemic action of sitagliptin by plasma active form glucagon-
AIM: To investigate whether active glucagon-like peptide-1 (GLP-1) is a prediction Factor of Effect of sitagliptin on pa......
Our previous investigation found that exendin-4 （Ex-4） , a peptide analogue of glucagon-like peptide 1 （GLP-1） , induced bon......
